Drug Trial Radar · NCT01235962
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Last checked: Nov 20, 2026Latest source record: Nov 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,538
Actual
Start
Nov 30, 2010
Primary completion
Oct 15, 2015
Study completion Apr 15, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.
Conditions
- Renal Cell Carcinoma (RCC)
- Cancer
Interventions
pazopanibDrug
Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
placeboDrug
Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
pazopanibDrug
Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
placeboDrug
placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. PlaceboTime frame: approximately 5 years
Locations
312 sites in 26 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Jonesboro, Arkansas
Novartis Investigative Site
Antioch, California
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Fresno, California
Novartis Investigative Site
La Jolla, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
South San Francisco, California
Novartis Investigative Site
Stanford, California
Novartis Investigative Site
Vallejo, California
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Washington D.C., District of Columbia
Novartis Investigative Site
Fort Myers, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Athens, Georgia
Novartis Investigative Site
Macon, Georgia
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Indianapolis, Indiana
Novartis Investigative Site
Iowa City, Iowa
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Burlington, Massachusetts
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Rochester, Minnesota
Novartis Investigative Site
Saint Louis Park, Minnesota
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Lincoln, Nebraska
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
Las Vegas, Nevada
Novartis Investigative Site
Hackensack, New Jersey
Novartis Investigative Site
Albany, New York
Novartis Investigative Site
Buffalo, New York
Novartis Investigative Site
New York, New York
Showing 40 of 312 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.